Migraine Treatment Medication Zecuity Receives FDA Approval

Migraine treatment medication Zecuity (formerly called Zelrix) has received FDA approval following a product redesign. The FDA had initially rejected the drug’s application for approval back in August 2011 because of concerns about chemistry and manufacturing.

Zecuity is a single-use patch that delivers sumatriptan through a mild, battery-powered electrical current. Although the medication sumatriptan is not new (in fact, it was the first triptan), the delivery mechanism utilized by Zecuity is extremely novel and exciting.

hm-migraine-patchThe Zecuity patch can be applied to the arm or thigh. Over a four hour period, the patch transmits sumatriptan through the skin. During this time a microprocessor in the patch monitors the resistance of the patient’s skin to absorption into the blood stream and adjusts delivery accordingly.

Zecuity is not just exciting because of the sophisticated technology it employs, however. It will also provide an additional, much needed treatment option for migraine patients that bypasses the gastrointestinal tract. This is essential because migraineurs experience something known as gastroparesis, which slows down the GI tract and makes it difficult for medications taken orally to take effect in a timely fashion.

The most common side effects associated with use of Zecuity are pain, itching, tingling, warmth or discomfort at the application site. Some patients experience redness at the application site after removing the patch, but this typically goes away within 24 hours. All the same contraindications carried by other triptans are equally applicable to Zecuity.

In NuPathe’s press release announcing the FDA decision, company CEO Armando Anido said they are currently looking for commercial partners and expect the product to be available to consumers toward the end of 2013.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
View References

Comments

View Comments (6)

Poll